INTRODUCTION
Despite its reported toxicity, the polyene antibiotic, amphotericin B (AmB), has found clinical applications in the treatment of systemic fungal infections in patients with cancer, AIDS, organ transplantation, and in parasitic disease [1] . Long term treatment with a conventional AmB therapy such as Fungizone ® (from here on simply stated as Fungizone), is associated with high incidence of renal impairment and hepatotoxicity [2] , [3] . The lipid-based formulations, Amphocil ® (colloidal dispersion) AmBisome ® (liposomes; from here on simply stated as AmBisome) and Abelcet ® (lipid complex) are more tolerable, offer better protection against the renal damage than
Fungizone and can be administered at a higher dosage in cases of severe systemic infections [4] , [5] . AmBisome could be administered up to 3-5 mg/kg daily with lower incidences of nephrotoxicity as compared with Fungizone, which is only licensed for a daily dose of 1mg/kg [6] , [7] . Although less nephrotoxic, the lipid-based AmB formulations are less efficacious than the conventional AmB formulations, meaning that higher doses are often required for desirable therapeutic effect which may subsequently lead to toxic manifestations [8] .
AmB's inherent low aqueous solubility poses many hurdles in the development of a suitable oral or injectable formulation. Both passive and active targeting approaches have been employed for delivering AmB. Passive delivery of AmB can be achieved using various polymeric systems, which being particulate in nature, are avidly taken up by macrophages due to their scavenging property [9] . A plethora of reports have shown that the polymeric nanoparticles are readily phagocytosed by macrophages [10] , [11] , [12] leading to the passive accumulation of the drug in the liver and spleen (macrophage rich organs). Interestingly, macrophage uptake could be further enhanced by attaching target specific ligands onto the nanoparticles [13] . Few examples of these actively targeting AmB nanocarriers include the pH-sensitive conjugates of AmBpoly(ethylene glycol) which selectively releases AmB at target site [14] , mannan or pullanan bearing liposomes loaded with AmB to target alveolar macrophages [15] , and a mannose-coated lipid nanospheres of AmB for specific targeting to reticluloendothelial macrophages [16] .
Several polymeric micelles based on diblock and triblock co-polymers [17] , [18] , [19] have the potential to solubilise AmB. However, micelles have the tendency to lose their integrity in serum mimicking conditions [20] , [21] , resulting in sudden 5 release, or burst, of drugs in an uncontrolled fashion [20] , [22] . An additional issue is that the encapsulation in the polymeric micelles resulted in the decrease of in vitro antifungal activity of the drug [23] , [17] . Other polymers such as polyvinyl-pyrrolidone possess the ability to complex AmB, but suffer from very low (0.249% w/w) AmB loading [24] . AmB-cyclodextrin complexes have shown improved water solubility [25] but demonstrate toxicity to human red blood cells [26] .
Biocompatible and water-soluble polymers, both synthetic and naturallyoccurring, have been extensively used to improve water solubility, optimise pharmacokinetics and improve drug efficacy and safety [27] . The naturally-occuring poly(gamma-glutamic acid) (PGGA) is known to be biodegradable, non-toxic, nonimmunogenic [28] , well-tolerated at high doses in preclinical studies [29] , and importantly is chemically modifiable owing to the presence of the pendant carboxylic groups [30] . PGGA can be obtained in large amounts at low production costs through engineering and optimization of various microbial fermentation processes [31] . Herein, we describe the development and evaluation of alternative AmB formulations using PGGA as the delivery vehicle. Through physicochemical and biological characterizations, we have been able to confirm that the as-synthesized AmB/PGGA complexes have a better safety profile as compared to Fungizone in vitro, and greater antifungal efficacy than both Fungizone and Ambisome in vivo. The data suggests that by employing a non-covalently associated polymeric nanocarrier, it is possible to overcome problems associated with delivering a potent but highly cytotoxic and hydrophobic drug such as AmB.
MATERIALS AND METHODS

AmB/PGGA complex synthesis
Degradation of high molecular weight PGGA In a typical alkaline hydrolysis reaction, PGGA of the free acid form (5 g, 34.45 mmol; 1500 kDa, Natto Biosciences) was dissolved in aqueous sodium bicarbonate (50 mL, 67.60 mM). The solution was heated to 90°C and NaOH (1.38 g, 34.45 mmol) was added. The solution was maintained at 90°C for 6 h, and then was left to cool to room temperature. The pH of the solution was adjusted to 7.0 with HCl, and subsequently treated with Amberlite resin (50 g, IR-120 H + type, 50 mesh Sigma-Aldrich). After 1 h, the Amberlite resin was separated from the mixture by filtration and washed with deionised water (50 mL). The filtrate was collected and kept at 2-8°C for 2 days prior 6 to further filtration to facilitate the precipitation of the polymer. The precipitate was collected and excess water was removed from the precipitate by freeze-drying. mm BBO probe inducing Z-axis pulse field gradients. Spectra were processed using TOPSPIN 1.3 software.
Characterisation of AmB/PGGA complex
Drug loading efficiency and aggregation state of AmB were ascertained by UVVis spectroscopy. TEM analysis was performed to analyse size and shape of the complex. The hydrodynamic particle size and zeta potential of the AmB/PGGA complexes were determined by Dynamic Light Scattering (DLS) technique using a
Zetasizer Nano ZS instrument (Malvern). Interactions between PGGA and AmB were analysed by HPLC using an Agilent Zorbax SB-C18 analytical column.
Stability of AmB/PGGA complexes in solution
The effect of storage conditions on the stability of AmB/PGGA complexes in solution after reconstitution in water was assessed over a 4-week period at 2-8° and room 25°C. 
In-vitro
Haemolysis assay
Preliminarily, acute drug toxicity was assessed through in vitro erythrocyte lysis test, wherein hemoglobin released as a result of membrane leakage or disruption caused by exposure to the drug formulation was measured.
Modulation of pro-inflammatory cytokines
PBMC were incubated with test samples (AmB/PGGA complexes of 55 kDa and 110 kDa, Fungizone and AmBisome) at various concentrations for 24 h at 37°C
and 5% CO2. After incubation for 24 h, the supernatants were collected and immunoassayed for the determination of the cytokines TNF-α and IL-1β using immunoassay kits Human TNF-α and IL-1β ELISA Ready-SET Go (eBioscience).
Assessment of antifungal efficacy in vivo
The Statistical analysis: data were analyzed by the Student's t-test and one way analysis of variance (Holm-Sidak method), using Sigma-Plot version 10 software. P-values <0.05
were considered to be statistically significant. 
RESULTS
Degradation of PGGA
Molecular weight determination by Gel Permeation Chromatography (GPC):
The results of PGGA degradation are shown in Table 1 . For the determination of molecular weight (MW) of the PGGA, the specific refractive index (dn/dc) of the 9 polymer was obtained from a plot of refractive index (IR) detector peak area versus the PGGA concentration (0 -10 mg/mL) at a fixed volume (1 mL); the slope of which corresponded to the dn/dc value (0.0939) ( Figure S1 ). The polymer MW was calculated using the Rayleigh equation:
Where R, K, C and M are the intensity of the scattered light, the optical constant, the concentration and MW of the polymer, respectively. Figure 1 shows the FT-IR spectra of the parent and degraded PGGA polymers, which are identical, except the parent PGGA produces higher intensity bands. The FT-IR spectra show a band at 3271.50 cm -1 which is characteristic of the N-H stretch, whilst a band that is indicative of the COOH group appears at 1446.06 cm -1 . In addition, the absence of additional peaks suggests that the degraded PGGA was of high purity. 
Analysis of degraded PGGA by FT-IR:
N-Hydroxysuccinimide (NHS) activation of PGGA
Determination of NHS activation:
The extent of NHS activation was determined using 1 H-NMR. Figure S2B shows an example of a 1 H-NMR spectrum of NHSactivated PGGA. The peak at 2.8 ppm corresponds to the protons of NHS; this peak is present in the final product in contrast to that of the starting polymer ( Figure S2A ), and is further downfield compared to the reference NHS peak (2.6 ppm, not shown)
indicating that the NHS moiety is now coupled to the polymer. In addition, the proton which corresponds to the α-carbon now appears downfield (4.15 ppm to 4.64 ppm), which provides further evidence that the NHS has coupled to PGGA. Using varying amounts of reactants, it was possible to achieve up to 91% of NHS substitution (Table   2 ). Table 3) . The complex appears spherical in structure (Figure 2A 
UV Spectroscopy Analysis
The UV spectra of the AmB/PGGA complex, Fungizone and AmBisome are shown in Figure 3 . In Fungizone, AmB exists predominantly as oligomeric aggregated species with a maximum absorption at 328 nm, whereas in the AmB/PGGA complex and AmBisome, AmB exists mostly as superaggregates with a maximum absorption at 322 nm. 
Stability of AmB/PGGA complexes in solution
The stability of AmB/PGGA complexes in solution after reconstitution in water was assessed over a 4-week period at refrigerated (2-8°) and room (25°C) temperatures (Table 4) . After 1 week, ≥98% AmB was retained within the both complexes at both temperatures. After 4 weeks, ≥91% AmB was found to remain associated with the polymer. In fact, both samples remained stable for 3 weeks when stored at 2-8°C whilst 11 solutions stored at 25°C lost >10% of AmB content by week 4. The data suggests that the stability of the complex is greater at 2-8°C. 
Haemolysis assays
Haemolytic activity of AmB/PGGA complexes, AmBisome and Fungizone were evaluated at 1 and 24 h as shown in Figure 4A and Figure 4A respectively.
Haemolysis was found to be AmB concentration-dependent, with Fungizone having the highest haemolytic activity, followed by AmB/PGGA complexes (with the lower polymer MW causing the higher haemolysis) and AmBisome, for both 1 and 24 h assays. Haemolysis was determined at time t = 1 and 24 h, expressed as % haemolysis at λ = 580 nm. 
Evaluation of in vitro antifungal activity
The antifungal activity of AmB formulations was evaluated by performing MIC and MFC determinations at the AmB concentration range of 0.03-16 μg/mL (original conc. = 32 μg/mL) with an inoculum size of ~1 x 10 4 CFU. 
Modulation of pro-inflammatory cytokine production
Regulation of the cytokines TNF-α and IL-1β was evaluated for AmB/PGGA complexes against the comparators, AmBisome and Fungizone ( Figures 5A and 5B ).
There were no significant differences between the formulations except for Fungizone, which caused the highest upregulation for both cytokines at the highest AmB concentration tested (2 μg/mL).
Figure 5. Cytokine release as a function of AmB concentration, produced by PBMCs in the presence of various AmB formulations: (A) TNF-α; (B) IL-1β. Data are means of triplicates (N=3).
Evaluation of in vivo antifungal efficacy
The efficacy of AmB/PGGA complexes was evaluated in mice infected with C.
albicans and were compared against Fungizone and AmBisome, with PBS as a control. followed by alkaline hydrolysis. Using varying amounts of reactants, it was possible to achieve lower MW polymer (Table 1) , with high purity as shown by F-TIR ( Figure 1) ; and up to 91% of NHS substitution ( Table 2) . As the drug and polymer underwent alkaline hydrolysis and transitioned from an organic medium to a predominantly aqueous medium, it was observed that the water-soluble AmB/PGGA complexes formed spontaneously, possibly via a mechanism of self-assembly. Although we did not verify this, PGGA or its derivatives have been known to form self-assembled, nanosized particles [32] . Several researchers have demonstrated the self-assembly formation of nano-carriers based on PGGA [33] , [34] ; with one recent study confirming the selfassemblage of PGGA nanoparticle by measuring CMC (critical micelle concentration) using pyrene as a hydrophobic probe [35] . In general, polymeric nanoparticles are often formed through self-assembly [36] , a process driven by the hydrophobic, hydrophilic and amphiphilic characteristics of the different (co)polymers. In contrast to conjugation methods, which often requires complex coupling chemistry, our method is comparatively simpler and highly efficient, achieving a consistent practical loading of 26.1 to 34.7% (w/w) (Table 3) , which compares well against 3.8% (w/w) and 45.5%
(w/w) for AmBisome and Fungizone, respectively. The data suggests that AmB/PGGA complexes can be formulated using only PGGA and no other excipients; this is an advantage over products that require many stabilising agents, since these excipients may cause toxicity and/ or incompatibility issues [37] .
Lyophilised AmB/PGGA complexes were found to be readily soluble in water, resulting in a clear solution. In contrast, the reconstitution of both AmBisome and
Fungizone involves a more complicated procedure that requires vigorous shaking, inspection or dilution [6], [7] . TEM imaging of the AmB/PGGA complexes revealed a uniform population of spherical nanoparticles with a mean diameter of 20-40 nm (Figure 2 ). The morphology of the complexes is similar to that reported by Yoo et al.
which, according to the author, is indicative of a polymeric micellar system [38] . It was hypothesised that the interaction between the carrier (PGGA) and the drug (AmB) was likely to be of a non-covalent nature. To test this hypothesis, the AmB/PGGA complex and the free AmB were analysed by HPLC using a hydrophobic column. As shown in Figure S3 , the elution times were similar between the AmB/PGGA complex and the free AmB, indicating that the interactions of AmB in the complex with a hydrophobic affinity column were therefore not affected by the forces that hold the polymeric carrier (PGGA) and AmB together. This suggests that the interactions between the PGGA and AmB were non-covalent rather than covalent because the latter would have affected the elution time of the AmB/PGGA complex.
Non-covalent complexes are known to suffer from the possible risk of drug loss from the drug carrier due to the weaker forces that hold the drug and the drug carrier as compared with a covalent drug-conjugate. We, therefore, investigated the stability of the AmB/PGGA complexes (55 and 110 kDa) in solution and found that both AmB/PGGA complexes retained more than 90% of AmB at 4°C, and more than 86%
of AmB at 25°C, after 4 weeks ( Table 4 ). The apparent high stability of the AmB/PGGA in solution could be due to the negative charge and the nanoscopic range of the complexes (∼-50 mV, and 90 -120 nm as measured by DLS, respectively) ( Table 3) .
Previous studies have reported that small and negatively charged particles have high stability, reduced interactions with blood components, as well as greater passive targeting and longer blood residence time [39] , [40] . AmB is known to interact freely with the cholesterol in red blood cells leading to severe haemolysis [45] , [46] . Haemolysis assays at 1 and 24 hours demonstrated that all three AmB/PGGA complexes caused significantly less haemolysis than Fungizone but greater than AmBisome, and the AmB/PGGA complex with the higher MW polymer to be less haemolytic (110 kDa< 65 kDa<55 kDa) ( Figure 4 ). Fungizone is highly haemolytic because it is formulated with the excipient, sodium deoxycholate, an anionic surfactant known to cause haemolysis [58] . Previously, low haemolytic activity has been attributed to the superaggregated form of AmB, found in AmBisome and in the heated solution of Fungizone; as indicated by a UV spectral shift of the maximum absorption from 328 nm to 322 nm [43] . Figure 3 confirms that AmB/PGGA complex too contains the superaggregated form of AmB, which is in accordance with a study conducted on a AmB formulation developed with a variant of PGA (poly L-glutamic acid) [46] , and thus provides an explanation for the observed lowered haemolytic activity of the AmB/PGGA complexes. It has been suggested that the regulated release of AmB from the polymer maintains the released drug in a monomeric form (since the concentration of the released drug remains below its CMC for aggregation), preventing it from forming oligomeric aggregates. Both monomer and super-aggregate forms of AmB are less toxic, while the oligomeric species are mainly responsible for the drug induced toxicity [47] . Moreover, only small amount of drug is available to bind to the red blood cell membrane due to the slow release, thereby reducing toxicity; although
this is yet to be tested experimentally.
The formulation process of the AmB/PGGA complexes did not affect the AmB Table 5 ).
The administration of conventional AmB is often associated with infusionrelated toxicity side effects such as fever and chills, as a result of the upregulation of proinflammatory cytokines, TNF-α and IL-1β [48] , [49] . In human peripheral blood mononuclear cells (PBMCs), it was found that Fungizone upregulated the production of both TNF-α and IL-1β, whereas the two AmB/PGGA complexes (55 and 110 kDa)
and AmBisome did not ( Figure 5 ). These findings also indirectly confirm clinical experience which reports greater incidence rates of infusion-related toxicity for Fungizone than AmBisome [48] . Based on these findings, it is reasonable to expect that AmB/PGGA complexes may have similar incidence rates of the aforementioned toxicity as with AmBisome.
The antifungal efficacy of two AmB/PGGA complexes was evaluated in experimental murine candidiasis. AmB/PGGA complexes were found to be more effective in clearing fungal burden in liver, spleen and kidney of infected animals than Fungizone were 80%, 50%, 30% and 0%, respectively ( Figure 6 ). Our data suggest that the AmB/PGGA complexes have a higher antifungal efficacy than both comparators.
The mechanism by which the AmB/PGGA complexes exert their greater antifungal efficacy is not known, although it has been suggested that the incorporation of PGGA into chitosan/siRNA and chitosan/DNA complexes enhances their cellular uptake and facilitates the unpacking of the complexes to release the payload upon cell entry [50] , [51] . It has also been reported that necrotizing vasculitis occurs during Candida infections [52] and the leaky blood vessels at these sites of inflammation may result in enhanced permeation of nanocarriers [53] . Overall, colloidal polymeric carriers including PGGA [10] , [11] , [12] , are naturally passively targeted to, or can be tailored to actively target, organs of reticuloendothelial system (RES); leading to greater distribution of AmB to liver and spleen, thereby effectively reducing the pathogen burden [16] . Biodistribution studies have shown that (passively targeted) Amphocil ® and Abelcet ® are rapidly accumulated in the mononuclear phagocyte system [54] . Incidentally, macrophages are heavily involved in inflammation and pathogenesis of many diseases such as candidiasis [55] ; thus may act as 'Trojan horses' [56] and carry encapsulated nanoparticles to the site of infection. Subsequently, nanoparticlebearing macrophages may act as 'secondary depot' or 'cellular drug reservoirs' of active drug entities [57] , gradually releasing it into the surrounding milieu [58] . Thus, macrophages may provide an indirect boost to microbial clearance as the drug can be delivered to the site of active pathogen growth [59] . Although initially demonstrated in cancer, this paradigm may be extended to other nano-encapsulated therapeutics and non-cancer disease indications [60] However, although PGGA has been consumed by humans over many centuries, it is still not known whether it would elicit immunogenicity when administered parenterally.
Future studies therefore should assess the immunogenicity potential of the AmB/PGGA complexes and confirm the enhanced efficacy that was observed in our animal models.
In our investigations, the AmB/PGGA complex with the higher molecular weight polymer performed better than that with lower molecular weight in terms of cytotoxicity and antifungal efficacy. It is thus recommended that the higher molecular weight AmB/PGGA complexes be further investigated.
